An end-to-end computational study that follows one gene from a transcriptomic signal to a structural hypothesis. Paired tumour/normal RNA-seq from colorectal cancer identifies the biology; functional enrichment interprets it; a ten-gene panel is locked and reproduced in an independent cohort; carbonic anhydrase VII (CA7) is carried into zinc-aware molecular docking; and the selected complex is tested for stability with molecular dynamics.
Every stage is documented — including the parts that failed, because those turned out to be the most informative.
Click the picture to open it at full resolution.
| Result | |
|---|---|
| Genes tested | 19,089 (6 patients, paired tumour vs normal) |
| Differentially expressed | 5,038 at FDR < 0.05 → 2,854 with |log₂FC| ≥ 1 (894 up, 1,960 down) |
| Biology | proliferation programmes up; differentiated colonic epithelium and transport lost |
| Independent validation | ten-gene panel reproduced 10/10 in a separate 34-patient cohort (97.8 % agreement) |
| Structural target | CA7 — log₂FC −5.06, padj 1.4 × 10⁻¹², 1.10 Å ligand-bound structure (PDB 8Q3U) |
| Standard docking | plain AutoDock Vina failed redocking (10.07 Å) — a scoring failure, not a search failure |
| Zinc-aware docking | only AutoDock4Zn + anionic sulfonamide recovered the zinc anchor — head group 0.785 Å, whole ligand 4.12 Å (partial validation) |
| 20-compound screen | Zn–N < 2.5 Å in 11/11 primary sulfonamides vs 0/9 controls; docking score did not separate the classes |
| Selected compound | chlorthalidone (ZINC000000057255), Zn–N 1.93 Å vs 1.94 Å crystallographic — a known CA inhibitor |
| Molecular dynamics | 6 ns, 41,271 atoms: Zn–N 2.214 ± 0.065 Å, four-coordinate in 100 % of frames, backbone RMSD 0.94 Å, 87.9 % of the ligand buried |
Every number above is re-derived from the result files, with its source, in
04_Report/REPORT_DATA_CHECK.md.
The full write-up is the report: 04_Report/FINAL_CRC_CA7_PROJECT_REPORT.pdf.
1 · RNA-seq and functional enrichment — 01_RNAseq/
Raw counts for GSE50760 (primary tumour and matched normal colon from six patients) were
analysed with DESeq2 using a patient-blocked design, ~ patient + condition, after filtering
to genes with ≥ 10 counts in ≥ 6 samples. The patient pairing was not in the supplied metadata
and was recovered from the GEO sample titles. Enrichment was run separately on up- and
down-regulated genes (GO Biological Process and KEGG with clusterProfiler) and over the full
ranked list (GSEA). One tumour sample clusters with the normals on PCA; it was flagged and kept,
since the paired design turns it into a loss of power rather than a source of false positives.
- Notebook:
CRC_RNAseq_GSE50760_analysis.ipynb(R kernel) — the whole RNA-seq analysis, plus sections 17–18 showing the docking and MD figures beside the PyMOL code that drew them - Scripts:
01_RNAseq/scripts/00–08(R), run in order - Record:
ANALYSIS_RECORD.md— decisions, figure log and limitations L1–L33
2 · Candidate panel and target selection — 01_RNAseq/
A ten-gene panel (KRT80, ETV4, CDH3, STC2, CGREF1 up; CA4, MS4A12, CLCA4, TMIGD1, CA7 down) was locked and not revised afterwards. All ten were confirmed protein-coding against NCBI and Ensembl, and all ten reproduced in an independent 34-patient cohort (GSE292858). CA7 was chosen for structural work because it combines a strong, reproducible expression change with unusually good structural resources. It is down-regulated in tumour, so it is treated as a structural and biomarker subject — not as a drug target for colorectal cancer.
3 · Zinc-site docking — 02_Docking/
The receptor was PDB 8Q3U (CA7, 1.10 Å) with the co-crystallised ligand, glycerol and all waters removed and the catalytic Zn²⁺ kept (4,219 atoms). Before screening, the crystallographic ligand J8I was re-docked as a control. Plain AutoDock Vina failed; the diagnosis showed the correct pose was being generated but mis-ranked, so more search could not fix it. A controlled 2 × 2 experiment (Vina vs AutoDock4Zn × neutral vs anionic sulfonamide) showed that only the combination recovered the zinc-binding head group.
Twenty ZINC20 compounds were then screened under identical settings (Vina 1.2.7 with
--scoring ad4, exhaustiveness 100, seed 5678, 20 modes): eleven primary sulfonamides, six
secondary sulfonamides as a hard negative control, and three compounds with no zinc-binding
group. Zinc-coordination geometry separated the classes perfectly; the docking score did not
— a secondary sulfonamide that cannot coordinate zinc at all scored second best. Chlorthalidone
was selected on mechanism and geometry, with score consulted last.
- Record:
DOCKING_RECORD.md— every run, including the failed ones and the Dockey ligand-substitution incident - Scripts:
02_Docking/scripts/01–26, numbered in the order they were run - Manifest of outputs:
results/FINAL_OUTPUTS.md
4 · Molecular dynamics — 03_Molecular_Dynamics/
The docked pose was carried into MD unchanged (verified to 0.000000 Å) and built in CHARMM-GUI with CHARMM36m, CGenFF, TIP3P and 0.15 M NaCl. It was minimised, equilibrated (125 ps NVT, 250 ps NPT with restraints) and run for 6 ns of unrestrained NPT production at 310 K in GROMACS 2026.3 on a GPU. The complex stayed intact, the protein fold was stable and the zinc coordination held throughout.
Two build failures are documented rather than hidden: a ligand atom-name mismatch between CHARMM-GUI modules, and a ligand that came back neutral because the MOL2 format cannot carry a formal charge — caught by auditing the generated topology, and rebuilt from SDF/SMILES.
- Report:
MD_FINAL_REPORT.md· run log:MD_RUN_LOG.md· CHARMM-GUI log:CHARMMGUI_RECORD.md - Run directory:
03_Molecular_Dynamics/md_run/withrun_md.sh - Analysis:
03_Molecular_Dynamics/scripts/05–08
Click any figure to open it at full size.
.
├── README.md this file
├── requirements.txt Python packages (docking, MD analysis, report)
├── docs/ the overview figure and the script that draws it
├── 01_RNAseq/ stage 1–2: RNA-seq, enrichment, validation, target selection
│ ├── CRC_RNAseq_GSE50760_analysis.ipynb
│ ├── ANALYSIS_RECORD.md
│ ├── data_raw/ GSE50760 counts + GSE292858 validation data
│ ├── scripts/ 00–08 (R), 09–10 (Python helpers)
│ ├── figures/ Figures 1–20
│ └── results/ DEG tables, enrichment, validation, target evidence
├── 02_Docking/ stage 3: receptor prep, redocking, AD4Zn screen
│ ├── DOCKING_RECORD.md
│ ├── inputs/ hand-prepared AutoDockTools files + Dockey run
│ ├── structures/ 8Q3U and the cleaned receptor
│ ├── scripts/ 01–26 (Python, PyMOL, batch)
│ ├── tools/ README only — third-party tools are not redistributed
│ └── results/ redocking, screen, final candidate, figures D2–D9
├── 03_Molecular_Dynamics/ stage 4: CHARMM-GUI build, GROMACS run, analysis
│ ├── MD_FINAL_REPORT.md, MD_RUN_LOG.md, CHARMMGUI_RECORD.md
│ ├── charmm-gui_8707215842_ligand/ ligand-parameterisation job (provenance)
│ ├── charmm-gui_8707261082_system/ system-building job (provenance)
│ ├── md_run/ GROMACS inputs, logs, energies, 6 × 1 ns trajectory
│ ├── scripts/ 01–08
│ └── results/ per-frame CSVs, Figures M1–M8, final-pose structures
└── 04_Report/ the written report (PDF + editable DOCX) and its build
Scripts resolve their paths relative to the repository, so they can be run from any working
directory. PyMOL .pml scripts are the exception: run them from inside their stage folder
(for example cd 02_Docking then pymol -cq scripts/21_pymol_D2_redocking.pml).
Software used
| Stage | Software |
|---|---|
| RNA-seq | R 4.6.1, Bioconductor 3.23 — DESeq2, apeglm, clusterProfiler, org.Hs.eg.db (01_RNAseq/scripts/00_install_packages.R) |
| Docking | AutoDock Vina 1.2.7, AutoGrid 4.2.6, AutoDock4Zn, MGLTools 1.5.7, RDKit 2026.03, Meeko 0.7.1, PyMOL 3.1 |
| MD | CHARMM-GUI (web), CHARMM36m + CGenFF, GROMACS 2026.3 (CUDA build via 03_Molecular_Dynamics/scripts/install_cuda_gromacs.sh), MDAnalysis 2.10, mdtraj 1.11 |
| Report | Python 3.11, Chrome (headless) for PDF, python-docx |
pip install -r requirements.txtRun order
- RNA-seq —
Rscript 01_RNAseq/scripts/00_install_packages.R, then scripts01→08in order (script04needs internet access for the KEGG REST API). Or open the notebook from inside01_RNAseq/. - Docking —
02_Docking/scripts/01→26in numbered order. Vina and the AutoDock4Zn tools must be installed first; see02_Docking/tools/README.md. - MD — the system was built in CHARMM-GUI (jobs 8707215842 and 8707261082, both archived
here). Production runs under WSL, from inside
03_Molecular_Dynamics/md_run/:GMX=~/miniforge3/envs/md/bin/gmx CNTMAX=6 bash run_md.sh all. The analysis scripts03_Molecular_Dynamics/scripts/05–08need only the trajectories included here. - Report —
python 04_Report/build/render.py, print04_Report/build/report.htmlto PDF, thenpython 04_Report/build/make_docx.py.
Left out to keep the repository small, all either regenerable or third-party:
| Excluded | How to get it back |
|---|---|
01_RNAseq/data_processed/*.rds (≈ 24 MB) |
written by running scripts 01–08 |
AutoGrid .map files (≈ 44 MB) |
regenerate from the saved .gpf — see 02_Docking/tools/README.md |
Vina / AutoGrid binaries, AD4Zn.dat, AutoDock4Zn helper scripts |
official sources in 02_Docking/tools/README.md |
GROMACS .tpr, .cpt, .trr, intermediate .gro, equilibration .xtc |
gmx grompp / run_md.sh from the included inputs and .mdp files |
CHARMM force-field folders (toppar/) inside the CHARMM-GUI jobs |
distributed by CHARMM-GUI; the GROMACS-format copy used for the run is in md_run/toppar/ |
This is computational structural evidence. Docking scores are scoring-function values, not binding affinities; a stable 6 ns trajectory shows the modelled complex is stable, not that chlorthalidone binds or inhibits CA7. Chlorthalidone is an established carbonic-anhydrase inhibitor, so selecting it is a coherence check on the protocol rather than a discovery. CA7 is down-regulated in colorectal cancer, and nothing here supports inhibiting it as a therapy.
The main limitations are stated alongside the results rather than buried: the redocking
validation is partial; the receptor is one rigid crystal conformation with its waters removed;
the zinc is a non-bonded ion in MD, so a −1 ligand beside a +2 point charge is attracted partly
for electrostatic reasons alone; CGenFF parameterised the deprotonated sulfonamide by analogy
to a sulfoximine (penalty 156.5); and there is a single 6 ns trajectory. The full list is in
01_RNAseq/ANALYSIS_RECORD.md (L1–L33) and
02_Docking/DOCKING_RECORD.md (D-L1–D-L19).
- GSE50760 — paired colorectal tumour / normal RNA-seq (NCBI GEO)
- GSE292858 — independent colorectal cancer cohort used for validation (NCBI GEO)
- PDB 8Q3U — human CA7 with the inhibitor J8I, 1.10 Å (RCSB PDB)
- UniProt P43166 — CA7 sequence and zinc-site annotation
- ZINC20 — the twenty screened compounds
Hossam Mahmoud El-Basiouny — all analyses, figures, records and the report.
Carried out as a Biotechnology Summer Project under the supervision of Prof. Abdo El-Fiky and Prof. Ahmed Adel, with the support of the teaching assistants Dr. Omnia Gaafer and Dr. Ibrahim M. Ibrahim.






















